Jefferies raised the firm’s price target on Argenx (ARGX) to $808 from $795 and keeps a Buy rating on the shares. The Vyvgart ADAPT SERON Phase 3 hit primary endpoint of day 29 myasthenia gravis activities of daily living change from baseline, the analyst tells investors in a research note. The firm increased its U.S. peak sales estimate for Vyvgart in myasthenia gravis to $3.8B.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target raised to $820 from $750 at Piper Sandler
- Argenx’s Vyvgart Shows Promising Phase III Results, Expanding Market Potential for Seronegative gMG Patients
- Argenx rises 6.0%
- Figma initiated, Okta upgraded: Wall Street’s top analyst calls
- argenx Reports Positive Results from ADAPT SERON Study for VYVGART